Radiology Case Reports 000 (2018) 1–4

Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier.com/locate/radcr

Case Report

Bladder diverticuli following injection of onabotulinum toxin A in a patient with multiple sclerosis and autosomal dominant polycystic kidney disease

Syed Imran Raza[a], *Ashkan Heshmatzadeh Behzadi*[a], *Jon D. Blumenfeld*[b,d], *Sarah K. Girardi*[c], *Martin R. Prince*[a,e,*]

[a] *Department of Radiology, Weill Cornell Medical College & New York Presbyterian Hospital, New York, NY, USA*
[b] *The Rogosin Institute, New York, NY, USA*
[c] *Department of Urology, North Shore University Hospital, Manhasset, New York, NY, USA*
[d] *Department of Medicine, Weill Cornell Medical College, New York, NY, USA*
[e] *Department of Radiology, Columbia University Medical Center, New York, NY, USA*

ARTICLE INFO

Article history:
Received 9 March 2018
Accepted 2 April 2018
Available online xxx

Keywords:
Bladder diverticuli
Onabotulinum toxin A
Botox
ADPKD
multiple sclerosis
MRI

ABSTRACT

Urinary incontinence due to neurogenic detrusor overactivity is common in patients with disorders of lower motor neurons controlling the bladder. Multiple sclerosis is a major cause of neurogenic detrusor overactivity, which negatively impacts quality of life. Bladder wall injection of onabotulinum toxin A can diminish spontaneous bladder contraction, urinary urgency, and urge incontinence. Herein we report a 61-year-old woman with multiple sclerosis and autosomal dominant polycystic kidney disease with bladder trabeculation developing after repeated injections of onabotulinum toxin A.

1. Introduction

Botulinum toxin treatment of overactive bladder is effective for patients who have failed conservative treatment and it has been approved for this indication by the Food and Drug Administration [1–3]. A recent meta-analysis by Drake et al indicated that 12 weeks of intravesicular injection of botulinum toxin (100 U) provides greater relief of overactive bladder symptoms than oral or transdermal anticholinergics, or mirabegron, a beta$_3$-receptor agonist [4]. Adverse effects of onabotulinum toxin A treatment include acute urinary retention (8.9%) [5], postoperative urinary tract infection (21.1%) [1], muscle weakness (2%-12%) [6], and autonomic dysfunction [7]. Hematuria (macroscopic) and bladder clots have also been reported in multiple studies [5,8].

* Corresponding author at: Department of Radiology, Weill Cornell University, 416 East 55th Street, New York, NY 10022, USA.
E-mail address: ash3002@med.cornell.edu (M.R. Prince).

https://doi.org/10.1016/j.radcr.2018.04.006



Fig. 1 – Coronal SSFP MRI of the bladder (a) prior to botox injection and (b) at presentation 3 months post the second bladder botox injection. Note the increased bladder wall thickness (solid white arrow) with multiple cyst-like diverticuli and thick trabeculations. Also note multiple cysts enlarging the liver (open white arrow) related to her ADPKD.

Table 1 – Bladder wall thickness and dimensions values at 3 time points.

Date of scan	Bladder wall thickness (mm)	Bladder wall dimensions (mm)	Number of diverticuli
2012	3.9	89.6 × 62.0	0
2014	4.5	97.5 × 52.8	1
2017	10.9	106.8 × 76.0	18

Table 2 – Laboratory results prior to botox injection and at presentation 3 months post the second bladder botox injection.

	Pretreatment (2013)	Posttreatment (2017)
Serum creatinine (mg/dL)	1.28	1.57
BUN (mg/dL)	21	40
BUN/creatinine ratio (ratio)	16	26
eGFR (mL/min/1.73 m^2)	43	33
Urine protein	23.9	91.2
Postvoidal residual volume (mL)	120	480

BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate.

2. Case report

A 61-year-old woman with multiple sclerosis (MS) and autosomal dominant polycystic kidney disease (ADPKD) underwent magnetic resonance imaging (MRI) abdomen and pelvis as part of her ongoing participation in The Rogosin Institute ADPKD Repository, a longitudinal observational study that includes biennial MRI [9]. She was diagnosed with MS approximately at the age of 35 years. Her urologic complications include overactive bladder with urge incontinence. Approximately at the age of 54 years, she was found to have a large postvoid residual volume (PVR). Prophylactic hexamethylenetetramine (Hiprex) effectively prevented urinary tract infection. Therefore an indwelling bladder catheter was not required.

Protocol MRI scans in 2012 and 2014 (Fig. 1) showed mild bladder trabeculation but no bladder diverticuli. The PVR was 120 mL prior to treatment with onabotulinum toxin A (Table 1).

In August 10, 2016, using cystoscopic guidance, a total of 200 units of onabotulinum toxin A (Botox) was reconstituted in 20 mL of sterile saline and injected in the detrusor muscle in 20 different locations in the posterior and lateral walls of the bladder (1.0 mL per location). The indications were lower urinary tract symptoms, including increasing urinary urgency and frequency. A follow-up injection of a total 200 units, using the same treatment protocol, was performed on February 8, 2017 (Fig. 2, Table 2).

There was symptomatic improvement in urinary urgency following onabotulinum toxin A treatment despite persistent elevated PVRs ~500 mL and 410 mL 1 and 2 months after each treatment, respectively.

A follow-up, protocol MRI of the abdomen in May 2017, 9 months after the first injection, and 3 months after the second injection of onabotulinum toxin A, showed interim development of severe bladder trabeculation and multiple bladder diverticuli. Hexamethylenetetramine was discontinued in response to the progression of her chronic kidney disease (Table 1).

After the MRI, a follow-up cystourethroscopy showed marked trabeculations and scattered diverticula throughout the urinary bladder confirming the MRI observations. These findings represent a change when compared with the cystoscopic findings 6 months prior and confirm the MRI findings.

3. Discussion

The novel findings observed by steady state free precession (SSFP) MRI images in this case are the development of severe

Please cite this article as: Syed Imran Raza et al., Bladder diverticuli following injection of onabotulinum toxin A in a patient with multiple sclerosis and autosomal dominant polycystic kidney disease, Radiology Case Reports (2018), https://doi.org/10.1016/j.radcr.2018.04.006